A study presented at the American Heart Association Scientific Sessions 2024 showed that tirzepatide, a drug used for diabetes treatment and weight management, can reduce major heart failure outcomes in patients with heart failure and obesity. The trial, called SUMMIT, demonstrated a 38% reduction in cardiovascular death or worsening heart failure events in patients who received tirzepatide compared to a placebo. The drug also improved health status, exercise tolerance, and reduced systemic inflammation. The study is significant for patients with heart failure and preserved ejection fraction (HFpEF) since there are limited treatment options available. Access to GLP-1 agonist drugs, including tirzepatide, remains a challenge due to high costs.
Source link
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
